Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Quantitative Evaluation of Human δ Opioid Receptor Desensitization Using the Operational Model of Drug Action

Edita Navratilova, Sue Waite, Dagmar Stropova, Miriam C. Eaton, Isabel D. Alves, Victor J. Hruby, William R. Roeske, Henry I. Yamamura and Eva V. Varga
Molecular Pharmacology May 2007, 71 (5) 1416-1426; DOI: https://doi.org/10.1124/mol.106.030023
Edita Navratilova
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sue Waite
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dagmar Stropova
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miriam C. Eaton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabel D. Alves
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victor J. Hruby
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William R. Roeske
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henry I. Yamamura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eva V. Varga
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Agonist-mediated desensitization of the opioid receptors is thought to function as a protective mechanism against sustained opioid signaling and therefore may prevent the development of opioid tolerance. However, the exact molecular mechanism of opioid receptor desensitization remains unresolved because of difficulties in measuring and interpreting receptor desensitization. In the present study, we investigated deltorphin II-mediated rapid desensitization of the human δ opioid receptors (hDOR) by measuring guanosine 5′-O-(3-[35S]thio)-triphosphate binding and inhibition of cAMP accumulation. We developed a mathematical analysis based on the operational model of agonist action (Black et al., 1985) to calculate the proportion of desensitized receptors. This approach permits a correct analysis of the complex process of functional desensitization by taking into account receptor-effector coupling and the time dependence of agonist pretreatment. Finally, we compared hDOR desensitization with receptor phosphorylation at Ser363, the translocation of β-arrestin2, and hDOR internalization. We found that in Chinese hamster ovary cells expressing the hDOR, deltorphin II treatment leads to phosphorylation of Ser363, translocation of β-arrestin2 to the plasma membrane, receptor internalization, and uncoupling from G proteins. It is noteworthy that mutation of the primary phosphorylation site Ser363 to alanine had virtually no effect on agonist-induced β-arrestin2 translocation and receptor internalization yet significantly attenuated receptor desensitization. These results strongly indicate that phosphorylation of Ser363 is the primary mechanism of hDOR desensitization.

Footnotes

  • This work was supported by National Institutes of Health grant DA06284.

  • Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.

  • doi:10.1124/mol.106.030023.

  • ABBREVIATIONS: hDOR, human δ opioid receptor; DOR, δ opioid receptor; GRK, G protein-coupled receptor kinase; CHO, Chinese hamster ovary; HEK, human embryonic kidney; IMDM, Iscove's modified Dulbecco's medium; GTPγ[35S], guanosine 5′-O-(3-[35S]thio)triphosphate; TE, Tris/EDTA buffer; GFP, green fluorescent protein.

    • Received August 22, 2006.
    • Accepted February 21, 2007.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 71 (5)
Molecular Pharmacology
Vol. 71, Issue 5
1 May 2007
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Quantitative Evaluation of Human δ Opioid Receptor Desensitization Using the Operational Model of Drug Action
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Quantitative Evaluation of Human δ Opioid Receptor Desensitization Using the Operational Model of Drug Action

Edita Navratilova, Sue Waite, Dagmar Stropova, Miriam C. Eaton, Isabel D. Alves, Victor J. Hruby, William R. Roeske, Henry I. Yamamura and Eva V. Varga
Molecular Pharmacology May 1, 2007, 71 (5) 1416-1426; DOI: https://doi.org/10.1124/mol.106.030023

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Quantitative Evaluation of Human δ Opioid Receptor Desensitization Using the Operational Model of Drug Action

Edita Navratilova, Sue Waite, Dagmar Stropova, Miriam C. Eaton, Isabel D. Alves, Victor J. Hruby, William R. Roeske, Henry I. Yamamura and Eva V. Varga
Molecular Pharmacology May 1, 2007, 71 (5) 1416-1426; DOI: https://doi.org/10.1124/mol.106.030023
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • EIPA, HMA and SMN2 gene regulation
  • Clc-2 has minor role in intestinal Cl- secretion
  • Resveratrol acts as an NR4A1 antagonist in lung cancer.
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics